Sunshine Biopharma, Inc., a pharmaceutical company researching life-saving medicines in oncology and antivirals, has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle (LNP) companies to advance the development of Sunshine Biopharma’s mRNA-based anticancer macromolecule, K1.1.   The collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma had prev...